FC
ALNY icon

Fayerweather Charles’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fayerweather Charles’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,960
Closed -$230K – 57
2017
Q3 		$230K Buy
+1,960
New +$167K 0.3% 60
2016
Q4 		– Sell
-4,165
Closed -$283K – 66
2016
Q3 		$283K Hold
4,165
– – 0.4% 61
2016
Q2 		$231K Buy
4,165
+140
+3% +$8.82K 0.32% 65
2016
Q1 		$253K Buy
4,025
+670
+20% +$44.5K 0.36% 64
2015
Q4 		$317K Buy
+3,355
New +$311K 0.52% 54

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM

Fayerweather Charles's ALNY Position: Q4 2017 in Review

Fayerweather Charles sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 1,960 shares — an estimated $230K sold.

Fayerweather Charles first reported a position in ALNY in Q4 2015 and held it in 5 quarters. The position peaked at $317K in Q4 2015. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Fayerweather Charles reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Fayerweather Charles sold 1,960 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $230K.
  • Fayerweather Charles first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Fayerweather Charles's Alnylam Pharmaceuticals position peaked at $317K in Q4 2015.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Fayerweather Charles's 13F filing for Q4 2017, filed 2 Feb 2018.